Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study (Q46173714)
Jump to navigation
Jump to search
scientific article published in January 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study |
scientific article published in January 2009 |
Statements
1 reference
Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study (English)
1 reference
M A Nauck
1 reference
G C Ellis
1 reference
P R Fleck
1 reference
C A Wilson
1 reference
Q Mekki
1 reference
Alogliptin Study 008 Group
1 reference
1 January 2009
1 reference
63
1 reference
1
1 reference
46-55
1 reference
Identifiers
1 reference
1 reference